The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations

Ki, Yoon; Lee, Ho Yun; Ahn, Myung‐Ju; Park, Keunchil; Ahn, Jin Seok; Sun, Jong‐Mu; Choi, Yoon‐La; Lee, Kyung Soo

doi:10.21037/jtd.2016.11.25

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there was a problem with the small number of subjects, other reasons were the inclusion of cases with unconfirmed EGFR mutations, the omission of important prognostic factors, or the inconsistent EGFR test methods or treatment processes within one study 18,19 . However, well-designed recent studies have reported that smoking history affects the efficacy of first-and 2nd-generation TKIs through multivariate analysis [20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

et al. 2022

View full text Add to dashboard Cite

The Institutional Review Board of Hallym University Sacred Heart Hospital approved the study protocol and informed consent was waived owing to the retrospective nature of the study (HALLYM 2020-03-016-001). All methods were carried out in accordance with the approved guidelines and regulations (Declaration of Helsinki). Data Sharing StatementThe dataset used and analysed during the present study is available from the corresponding author upon reasonable request.

show abstract

Section: Discussionmentioning

confidence: 99%

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

et al. 2022

View full text Add to dashboard Cite

show abstract

“…KRAS mutations generally mark a poor prognosis and are associated with intrinsic EGFR tyrosine kinase inhibitor (TKI) resistance. Never-smokers have demonstrated better therapeutic responses to EGFR TKIs, probably due to the higher occurrence of EGFR mutations in never-smokers [9]. Several studies have proposed mechanisms of resistance to EGFR TKIs related to smoking.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Cigarette Smoking in Association with Histologic Subtypes of Resected Lung Adenocarcinoma

Choi

Jeong

et al. 2019

Korean J Thorac Cardiovasc Surg

View full text Add to dashboard Cite

BackgroundSmokers with lung adenocarcinoma have a worse prognosis than those who have never smoked; the reasons for this are unclear. We aimed to elucidate the impact of smoking on patients’ prognosis and the association between smoking and clinicopathologic factors, particularly histologic subtypes.MethodsWe reviewed the records of 233 patients with pathologic stage T1-4N0-2M0 lung adenocarcinomas who underwent surgery between January 2004 and July 2015. The histologic subtypes of tumors were reassessed according to the 2015 World Health Organization classification.ResultsIn total, 114 patients had a history of smoking. The overall survival probabilities differed between never-smokers and ever-smokers (80.8% and 65.1%, respectively; p=0.003). In multivariate analyses, the predominant histologic subtype was an independent poor prognostic factor. Smoking history and tumor size >3 cm were independent predictors of solid or micropapillary (SOL/MIP)-predominance in the logistic regression analysis. Smoking quantity (pack-years) in patients with SOL/MIP-predominant tumors was greater than in those with lepidic-predominant tumors (p=0.000). However, there was no significant difference in smoking quantity between patients with SOL/MIP-predominant tumors and those whose tumors had non-predominant SOL/MIP components (p=0.150).ConclusionSmoking was found to be closely associated with SOL/MIP-predominance in lung adenocarcinoma. Greater smoking quantity was related to the presence of a SOL/MIP component.

show abstract

New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment

Wang,

Sun,

Lam

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths worldwide. Despite never smokers comprising between 10 and 25% of all cases, lung cancer in never smokers (LCNS) is relatively under characterized from an etiological and biological perspective. The application of multi-omics techniques on large patient cohorts has significantly advanced the current understanding of LCNS tumor biology. By synthesizing the findings of multi-omics studies on LCNS from a clinical perspective, we can directly translate knowledge regarding tumor biology into implications for patient care. Primarily focused on never smokers with lung adenocarcinoma, this review details the predominance of driver mutations, particularly in East Asian patients, as well as the frequency and importance of germline variants in LCNS. The mutational patterns present in LCNS tumors are thoroughly explored, highlighting the high abundance of the APOBEC signature. Moreover, this review recognizes the spectrum of immune profiles present in LCNS tumors and posits how it can be translated to treatment selection. The recurring and novel insights from multi-omics studies on LCNS tumor biology have a wide range of clinical implications. Risk factors such as exposure to outdoor air pollution, second hand smoke, and potentially diet have a genomic imprint in LCNS at varying degrees, and although they do not encompass all LCNS cases, they can be leveraged to stratify risk. Germline variants similarly contribute to a notable proportion of LCNS, which warrants detailed documentation of family history of lung cancer among never smokers and demonstrates value in developing testing for pathogenic variants in never smokers for early detection in the future. Molecular driver subtypes and specific co-mutations and mutational signatures have prognostic value in LCNS and can guide treatment selection. LCNS tumors with no known driver alterations tend to be stem-like and genes contributing to this state may serve as potential therapeutic targets. Overall, the comprehensive findings of multi-omics studies exert a wide influence on clinical management and future research directions in the realm of LCNS.

show abstract

The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations

Cited by 3 publications

References 39 publications

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

Prognostic Significance of Cigarette Smoking in Association with Histologic Subtypes of Resected Lung Adenocarcinoma

New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment

Contact Info

Product

Resources

About